MyFinsight
Home
Blog
About
Contact
Download
Download image
Maturities of investments
$1,531,136K
Proceeds from issuance of
shares through...
$13,005K
Sales of investments
$174,690K
Net cash provided by
(used in) investing...
$437,354K
Effect of exchange rate
changes on cash and cash...
$2,439K
Net cash provided by
financing activities
$2,014K
Canceled cashflow
$1,268,472K
Canceled cashflow
$10,991K
Net decrease in
cash, cash...
-$213,770K
Canceled cashflow
$441,807K
Stock-based compensation
expense
$138,845K
Operating lease
liabilities
$46,371K
Accrued contract
manufacturing expenses
$31,059K
Accounts payable
$19,906K
Depreciation and
amortization
$16,396K
Amortization of operating
lease right-of-use...
$8,464K
Accrued expenses
$5,967K
Accrued compensation
$2,302K
Purchases of investments
$1,211,499K
Purchases of
manufacturing facility...
$43,260K
Purchases of property and
equipment
$13,713K
Taxes paid related to
the net share...
$10,991K
Net cash used in
operating activities
-$655,577K
Canceled cashflow
$269,310K
Net loss
-$766,628K
Operating lease
right-of-use assets
$52,371K
Other assets
$39,886K
Unrealized foreign
exchange loss (gain)
$34,768K
Prepaid expenses and
other current assets
$16,800K
Net accretion of
discounts on investments
$14,434K
Back
Back
Cash Flow
source: myfinsight.com
Vaxcyte, Inc. (PCVX)
Vaxcyte, Inc. (PCVX)